Genetic polymorphisms have been found to affect SLC22A4 gene expression and to be associated with autoimmune diseases such as rheumatoid arthritis (RA),CD and type 1 diabetes (T1D) [12–14]. Here, SLC22A4 is linked to autoimmune disease.